Skip to main content
Clinical Trials/NCT02864121
NCT02864121
Completed
Not Applicable

Association Between High-risk HPV Genome Integration Detected by Molecular Combing and Cervical Lesions Severity and/or Evolution

CHU de Reims1 site in 1 country407 target enrollmentDecember 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Abnormal Cytology
Sponsor
CHU de Reims
Enrollment
407
Locations
1
Primary Endpoint
presence of high-risk papillomavirus in the analysis of cervical smear
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

High-risk human papillomavirus (HR-HPV) are involved in cervical cancer development. Integration of HR-HPV DNA in cellular genomes is considered as a major event in the cervical cancer development. The aim of this study is to validate the integration of the HPV-HR as an appropriate biomarker of the severity of precancerous lesions and progression of cervical lesions towards cervical cancer. HR-HPV integration status will be analyzed by Molecular Combing technology, which allows direct and high-resolution visualization of the integration of high-risk HPV genomes.

Registry
clinicaltrials.gov
Start Date
December 2015
End Date
December 17, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • women aged from 25 to 65 years
  • consulting in a gynecological-obstetrical service of one of the investigator center for a colposcopy reflex after an abnormal cytology dating of less than 6 months and more than 1 month
  • signature of the informed consent
  • affiliated to Social Security

Exclusion Criteria

  • women vaccinated against HPV
  • women who received a treatment for a cervical pathology followed by a normal
  • women with a known positive HIV test
  • women suffering from a chronic pathology that generate immunosuppression
  • Women currently treated with immunosuppressors
  • Women treated with corticoids currently or dating of less than 6 months
  • protected by law

Outcomes

Primary Outcomes

presence of high-risk papillomavirus in the analysis of cervical smear

Time Frame: during 36 months after inclusion

integration of genome of high-risk papillomavirus detected in cervical smear according molecular combing

Time Frame: during 36 months after inclusion

presence and severity of cervical lesion according to results of cervical smear, colonoscopy and histological analysis

Time Frame: during 36 months after inclusion

Study Sites (1)

Loading locations...

Similar Trials